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Abstract
Aims/hypothesis Autoantibodies directed at single islet
autoantigens are associated with lower overall risk of type 1
diabetes than multiple autoantibodies, but individuals with
one autoantibody may progress to higher risk categories. We
examined the characteristics of this progression in relatives
followed prospectively in the TrialNet Pathway to Prevention.
Methods The study population comprised 983 relatives who
were single autoantibody positive with normal baseline
glucose tolerance (median age 16.2 years). Samples were
screened for antibodies to GAD, insulinoma-associated anti-
gen 2 (IA-2) and insulin, and all positive samples tested for
antibodies to zinc transporter 8 and islet cell antibodies.
Results Antibodies to at least one additional islet autoantigen
appeared in 118 of 983 relatives (overall 5 year risk 22%, 95%
CI [17.9, 26.1]). At baseline, antibodies to GAD alone (68%)
were more frequent than antibodies to insulin (26%) or IA-2
(6%), but all were associated with a similar risk of developing
additional autoantibodies. Risk was associated with younger age
(p=0.002) and HLA class II genotype, but was similar in high
and intermediate genetic risk groups (p=0.65). Relatives who
becamemultiple autoantibody positive during the follow-up had
increased risk of developing diabetes comparable with the risk
in relatives with multiple autoantibodies at study entry.
Conclusions/interpretation Progression of islet autoimmunity
in single autoantibody positive relatives in late childhood/
adult life is associated with a predominance of autoantibodies
to GAD and a distinct HLA risk profile. This heterogeneity in
type 1 diabetes autoimmunity has potentially important impli-
cations for disease prevention.
Keywords Autoantigens . Diabetes antibodies . GAD .
HLA . IA-2 . Insulin autoantibodies . Islet autoantibodies .
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Abbreviations
BDC Barbara Davis Center for Childhood Diabetes
DK Digestive and Kidney
GADA Antibodies to GAD
IA-2 Insulinoma-associated antigen 2
IA-2A Antibodies to insulinoma-associated antigen 2
IAA Insulin autoantibodies
ICA Islet cell antibodies
NIDDK National Institute of Diabetes and Digestive and
Kidney Diseases
PTP Pathway to Prevention
ZnT8A Antibodies to zinc transporter 8
Introduction
The prodrome leading up to clinical onset of type 1 diabetes
has been increasingly well characterised over the last three
decades as the result of prospective study of relatives of
people with the condition and particularly birth cohort studies
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in children with markers of high genetic risk [1].We know that
antibodies to islet autoantigens typically appear early in life,
and may be present for some 30 years before diabetes
develops. Individuals with antibodies to more than one islet
autoantigen are at greatest risk and there is an increasing body
of evidence that, in the long term, almost all people with
multiple autoantibodies seem likely to develop diabetes
[2–5]. In infants at high genetic risk, the progression from
detection of a single islet autoantibody to the strongly
disease-associated pattern of multiple autoantibody positivity
and thence to overt diabetes usually occurs relatively rapidly
[6–8]. In the combined dataset from BabyDiab, Diabetes
Autoimmunity Study in the Young (DAISY) and Type 1
Diabetes Prediction and Prevention Project (DIPP) cohorts,
the median age of seroconversion for multiple autoantibodies
was 2.1 years, the cumulative risk of diabetes within 15 years of
seroconversion was 84% and the median time to diabetes was
3.5 years [5].We know that the risks of diabetes associated with
a detection of antibodies to a single islet autoantigen are five- to
eightfold lower than this and that some children develop single
autoantibodies for the first time in later childhood and adoles-
cence [2, 3, 6–9], but the natural history and determinants of
progression to diabetes in this group are less well understood.
Our aim was to examine the characteristics of development
of multiple islet autoantibodies and diabetes in single antibody
positive relatives of people with type 1 diabetes taking part in
a large prospective study. We set out to determine the risk of
progression from single to multiple autoantibody positive
status and to diabetes in a large cohort of relatives with normal
glucose tolerance followed prospectively in TrialNet studies,
and to examine the effect of demographic, genetic and
autoantibody characteristics on these risks.
Methods
Non-diabetic first, second and third degree relatives of people
with type 1 diabetes were recruited to the TrialNet Natural
History Study of the Development of Type 1 Diabetes
(Pathway to Prevention [PTP]; ClinicalTrials.gov identifier:
NCT00097292) as previously described [10]. All study
participants gave informed consent and the study was
approved by the responsible ethics committee for each study
site. Participants were included in this analysis if they had
antibodies to the same single islet autoantigen (GAD
[GADA], insulin [IAA] or insulinoma-associated antigen
2/ICA512 [IA-2A]) on at least two occasions and antibody
results were available from at least one subsequent study visit.
All samples were screened for GADA, IAA and IA-2A and, if
levels any of these were above the threshold of positivity, test-
ing for islet cell antibodies (ICA) and antibodies to zinc trans-
porter 8 (ZnT8A) was added. Individuals with confirmed islet
autoantibodies underwent baseline assessment including oral
glucose tolerance testing and were followed 6–12 monthly in
accordance with the PTP study protocol. From 2004 to 2012,
single autoantibody positive relatives were invited for
6-monthly visits including antibody determination and OGTT.
Since 2012, single autoantibody positive relatives with normal
glucose tolerance, HbA1c and a diabetes low risk score [11]
have been followed with 12-monthly islet autoantibody testing
and HbA1c determination. Individuals with abnormal glucose
tolerance at baseline and those carrying the protective HLA
class II haplotype DQA1*01:02-DQB1*06:02 were excluded
from the analysis.
Assays GADA, IAA, IA-2A and ZnT8A were measured by
radioimmunoassay in the TrialNet Core laboratory at the
Barbara Davis Center for Childhood Diabetes (BDC) as
previously described [9]. Up to 2010, antibodies to GAD
and ICA512 were tested in a combined assay using
3H-leucine-labelled GAD65 and
35S-methionine-labelled
ICA512—the ‘BDC in-house’ assay—with results
expressed as an index. Since June 2010, the laboratory
has used the harmonised GADA and IA-2A assays for
National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) Consortia [12]. The major differences
are that, in the harmonised assays: (1) the antibodies are mea-
sured separately using 35S-methionine-labelled in vitro tran-
scribed and translated GAD65 and IA-2; (2) results are
expressed in Digestive and Kidney (DK) units/ml derived from
standard curves made up of dilutions of common positive and
negative NIDDK working calibrators; and (3) thresholds have
been defined as equivalent to the 97th percentile in 500 adult
blood donor controls. In a comparison of the BDC in-house and
harmonised assays in 2,170 TrialNet PTP samples, designation
of positive/negative status was 96% concordant for GADA and
95% concordant for antibodies to ICA512/IA-2A. GAD and
IA-2/ICA512 antibody positive status was based on the results
of harmonised assays if available, and otherwise on the
in-house BDC assay. ICA were assayed by indirect immuno-
fluorescence at the University of Florida (Gainesville, FL,
USA). Assay quality assurance is under regular review by the
TrialNet Laboratory Monitoring Committee. In the 2012 Islet
Autoantibody Standardization Programme proficiency evalua-
tion, the BDC in-house assays for GADA, ICA512/IA-2A,
IAA and ZnT8A achieved 64%, 60%, 50% and 62% sensitivity
with 100%, 100%, 100% and 98% specificity, respectively. The
harmonised GADA and IA-2A assays achieved 66% and 70%
sensitivity with 99% and 100% specificity, respectively.
HLA-DQ polymorphisms were determined by allele-
specific oligonucleotide genotyping [9, 13]. The haplotypes
of interest were DQA1*05:01-DQB1*02:01 (DQ2),
DQA1*03:01-DQB1*03:02 (DQ8) and DQA1*01:02-
DQB1*06:02 (DQ6). HLA class II genotypes were defined
as high (DQ2/DQ8), moderate (DQ2/DQ2, DQ8/DQ8 or
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DQ8/X) or low risk (DQ6/X, DQ2/X or DQX/X) where X
represents a haplotype other than DQ2 or DQ8.
Statistical analysis The main outcome was the confirmed
development of multiple autoantibodies defined as
detection on two occasions of at least two of the five
islet autoantibodies included in the testing strategy
(GADA, IAA, IA-2A, ZnT8A and ICA). Diabetes was
defined by WHO criteria. Time-to-event analysis using
the Kaplan–Meier method was done to examine progres-
sion from single autoantibody positivity to development
of multiple autoantibodies and diabetes, as well as from
development of multiple antibodies to diabetes. The
time-to-event was calculated from the date of first
detection of a single islet autoantibody to date of first
detection of multiple autoantibodies, diagnosis of diabe-
tes or last follow-up. Logrank testing was used to com-
pare the cumulative incidence of development of
multiple autoantibodies or diabetes between groups.
Time to onset of development of multiple autoantibodies
by individual and combined risk markers, including age
at initial screening, sex, race, ethnicity, relationship to
the proband, antibody type and HLA class II genotype
was assessed by Cox proportional hazards regression
model. The effect of initial antibody titre was further
analysed within subgroups defined by antibody type.
Stratified Kaplan–Meier curves were generated for vari-
ables shown to be significant in the multivariable
model. For continuous variables (age and antibody
titre), optimal cutpoints were identified using forward
stepwise Cox proportional hazard regression models
over a range of possible thresholds. For each variable
the optimal cutpoint was that giving the highest level of
significance. Analyses including GADA and IA-2A titre
were restricted to samples for which BDC in-house
assay results were available.
Table 1 Participant characteristics
Single, confirmed antibody
positive (983 individuals)
Progressed to confirmed multiple
antibody positive (118 individuals)
Age at screening
Median (interquartile range) 16.2 (8.7–36.2) 11.0 (6.5–24.0)
<6 years 138 (14.0) 28 (23.7)
6–12 years 279 (28.4) 47 (39.8)
13–24 years 167 (17.0) 14 (11.9)
≥25 years 399 (40.6) 29 (24.6)
Sex
Male 394 (40.3) 60 (50.8)
Female 583 (59.7) 58 (49.2)
Race
White 812 (84.8) 111 (96.5)
Non-white 146 (15.2) 4 (3.5)
Ethnicity
Hispanic or Latino 151 (15.6) 4 (3.5)
Not Hispanic or Latino 793 (82.1) 110 (95.6)
Unknown 22 (2.3) 1 (0.9)
Relation to the type 1 diabetic proband
Sibling 390 (40.1) 65 (56.0)
Offspring 166 (17.1) 24 (20.7)
Othera 114 (11.7) 8 (6.9)
Parent 302 (31.1) 19 (16.4)
HLA risk
High: DQ2/DQ8 110 (13.6) 20 (18.2)
Moderate: DQ2/DQ2, DQ8/DQ8 or DQ8/DQX 311 (38.5) 55 (50.0)
Low: DQX/DQX or DQ2/DQXb 387 (47.9) 35 (31.8)
All values are n (%) unless otherwise indicated
a Second or third degree relatives of a person with type 1 diabetes and, aged ≤20 years at study entry
b Individuals with DQ6 genotypes were excluded from the analysis
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Results
Of 119,074 relatives screened in the TrialNet PTP by April
2013, 1,195 had confirmed antibodies to only one islet
autoantigen (GADA, IAA or IA-2A/ICA512 without ICA or
ZnT8A). Of these, 983 had normal glucose tolerance at base-
line and were therefore eligible for inclusion in the analysis.
The median age of these participants was 16.2 years (inter-
quartile range 8.7–36.2), 60% were female and 85% were
white. Of the 983 relatives, 672 (68%) were positive for
GADA, 252 (26%) for IAA and 59 (6%) for IA-2A. Other
characteristics are given in Table 1.
Development of additional autoantibodies The median
follow-up of the cohort was 2.2 years, duringwhich 118 relatives
with confirmed single autoantibody positivity developed anti-
bodies to at least one additional islet autoantigen. Of these, 82
were GADA positive in the initial sample, 27 were IAA positive
and nine IA-2A positive. The time from initial confirmed single
islet autoantibody to first confirmed detection of at least one
additional autoantibody is shown in Fig. 1a, and details of the
additional autoantibodies detected are given in electronic
supplementarymaterial (ESM) Table 1. Among the 118 relatives
who developed additional autoantibodies, 44were categorised as
multiple autoantibody positive only on the basis of detection of
ICA in follow-up samples; 40 with GADA and ICA, and four
with IAA and ICA. The median age at detection of the second
autoantibody was 12.7 (7.8–26.4). The overall 5 year risk of
becoming positive for multiple autoantibodies was 22.0%
(95%CI [17.9, 26.1]). Risks were higher in younger participants
(Fig. 1b). The 5 year-risk below the optimal cutpoint for age,
13 years, was 28.5% (22.2, 34.8) compared with 16.5%
(11.0, 22.0) in relatives above age 13 (p<0.001); 25.9% (19.4,
32.4) in males and 19.5% (14.2, 24.8) in females (p=0.008);
23.9% (19.4, 28.4) in white individuals compared with 10.1%
(0, 21.5) in non-white individuals (p=0.002); and 37.6%
(20.4, 54.8), 30.8% (22.8, 38.8) and 17.0% (11.3, 22.7), respec-
tively, in individuals with high,moderate and low riskHLA class
II genotypes (p=0.001). Initial antibody type did not influence
the risk of developing additional autoantibodies; risks were
similar in the groups with antibodies to GAD, insulin or
IA-2/ICA512 (Fig. 1c). The results of Cox proportional hazards
regression are shown in Table 2. On multivariable analysis, age
at screening, race and HLA class II genotype, but not sex, were
confirmed to be independent determinants of risk.
In 450 GADA positive individuals for whom BDC
in-house assay results were available, risk of developing
additional autoantibodies was influenced by initial antibody
titre (multivariable HR 4.4 [2.0, 9.5], p<0.001). The 5 year
risk in those with GADA index ≥0.2 (the optimal standard
assay cutpoint) was 45.3% (34.9, 55.7) compared with 8.4%
(4.5, 12.3) in those with GADA index <0.2 (p<0.001). A
similar effect was seen in 229 individuals with harmonised
GADA assay results though the median duration of follow-up
was shorter (0.88 years); the risk of developing additional
autoantibodies within 2 years was 33.1% (1.2, 65.0) in
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Fig. 1 (a) Time from initial detection of confirmed antibodies to a single
islet antigen (GAD, IA-2/ICA512 or insulin) to first detection of
confirmed multiple antibodies. The number of individuals at risk at the
start of each year of follow-up is shown below each graph. (b) Time from
initial detection of confirmed antibodies to a single islet antigen (GAD,
IA-2/ICA512 or insulin) to first detection of confirmed multiple antibod-
ies in relatives aged <13 years (black line) and ≥13 years (grey line)
(logrank test, p<0.001). (c) Time from initial detection of confirmed
antibodies to a single islet antigen (GAD [black line], IA-2/ICA512 [grey
line] or insulin [dashed line]) to first detection of confirmed multiple
antibodies (logrank test, p=0.38)
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participants with GADA ≥220 DK units/ml (the optimal
harmonised assay cutpoint) compared with 4.9% (0.6, 9.2)
with GADA <220 DK units/ml (p=0.001). Associations
between IAA and IA-2A titres and risk of becoming multi-
ple autoantibody positive could not be assessed owing to
the small number of individuals who developed additional
autoantibodies.
Risk of developing additional antibodies was similar in
participants carrying high compared with moderate risk
HLA class II genotypes (multivariable HR 1.13 [0.68, 1.88],
p=0.65). Among those with moderate risk genotypes, the
5 year risk did not differ between those carrying DQ2/DQ2
and DQ8/DQ8 (33% [11, 54] and 56% [36, 77], respectively,
p=0.16).
Progression to diabetes A total of 28 single autoantibody
positive relatives with normal glucose tolerance at baseline
progressed to diabetes. Of these, 20 (71%) were GADA
positive in the initial sample, 7 (25%) were IAA positive
and 1 (4%) was IA-2A positive. The median time to diagnosis
was 2.7 years. The overall 5 year risk of developing diabetes
was 6.6% (3.9, 9.3); and did not differ between participants
with GADA (6% [4.7, 12.5]), IAA (3.9% [0.8, 7.0]) or IA-2A
(0%) at baseline (p=0.66) (Fig. 2a). Of those who developed
diabetes, ten were multiple autoantibody positive in at least
one follow-up sample prior to diagnosis. The 5 year risk of
diabetes after first detection of multiple islet autoantibodies in
previously single antibody positive relatives was 24.5%
(8.8, 40.2), compared with 5.7% (3.0, 8.4) in participants
who remained positive for only one autoantibody
(p<0.0001), and was not different from the 5 year risk in
participants in the PTP study whowere found to havemultiple
antibodies at the initial screening visit (36.8% ([33.9, 39.7],
p=0.06)) (Fig. 2b).
Discussion
In this study, we found that relatives persistently positive for
antibodies to a single islet autoantigen had a 22% cumulative
Table 2 Cox proportional haz-
ards regression for time from ini-
tial confirmed single autoanti-
body positive to first confirmed
multiple autoantibody positive
(overall n=983)
Univariate HR
(95% CI)
p value Multivariable HR
(95% CI)
p value
Age at screening 0.97 (0.96, 0.99) <0.001 0.96 (0.93, 0.98) 0.002
Sex
Male 1.63 (1.13, 2.33) 0.008 1.28 (0.86, 1.90) 0.23
Female Ref. Ref.
Race
White 4.37 (1.61, 11.84) 0.004 4.23 (1.23, 14.53) 0.02
Non-white Ref. Ref.
Ethnicity
Hispanic or Latino 0.20 (0.08, 0.55) 0.002 0.31 (0.10, 1.02) 0.05
Not Hispanic or Latino Ref. Ref.
Unknown 0.45 (0.06, 3.24) 0.43 2.06 (0.25, 17.24) 0.50
Relation to type 1 diabetic proband
Sibling 2.83 (1.70, 4.72) <0.0001 1.03 (0.40, 2.52) 0.99
Offspring 2.12 (1.16, 3.87) 0.01 0.80 (0.30, 2.16) 0.66
Othera 0.93 (0.41, 2.13) 0.87 0.48 (0.15, 1.56) 0.22
Parent Ref. Ref.
Single antibody type
GADA Ref. Ref.
IA-2A/ICA512 1.09 (0.54, 2.16) 0.81 1.29 (0.62, 2.70) 0.50
IAA 0.75 (0.48, 1.15) 0.19 0.70 (0.44, 1.12) 0.14
HLA risk
High: DQ2/DQ8 2.24 (1.29, 3.88) 0.004 1.98 (1.11, 3.52)
Moderate: DQ2/DQ2,
DQ8/DQ8 or DQ8/DQX
2.00 (1.31, 3.06) 0.001 1.89 (1.21, 2.94) 0.02
Low: DQX/X or DQ2/Xb Ref. Ref. 0.005
a Second or third degree relatives of a person with type 1 diabetes, aged ≤20 years at study entry
b Individuals with DQ6 genotypes were excluded from the analysis
Ref., reference
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risk of progressing to the more strongly disease-associated
patternwith antibodies tomultiple autoantigenswithin 5 years.
Development of additional autoantibodies was not restricted
to early childhood, but occurred also in late childhood and
adult life. Risk was not influenced by initial autoantibody
type, but was related to antibody titre among those with
GADA.While the overall risk of early progression to diabetes
among single autoantibody positive relatives was relatively
low, we have shown that it was higher in those who developed
additional antibodies.
A major strength of this study is the size of the study cohort
followed up 6–12 monthly using a standard protocol. The
wide age range of the participants and the inclusion of rela-
tives carrying low and intermediate as well as high risk HLA
class genotypes mean that our findings complement those
from prospective studies from birth. Our study does, however,
have some limitations. The TrialNet PTP study protocol
meant that rescreening was not offered to adults if no antibod-
ies were detected in the initial samples and, even in children,
uptake for rescreening was relatively low. Some relatives who
were initially autoantibody negative relatives but subsequently
seroconverted to autoantibody positivity might therefore have
been missed. In addition, because the cohort was not followed
from birth, we are not able to exclude the possibility that some
of the participants were previously positive for other autoanti-
bodies as well as those detected in the first and confirmatory
study samples. A further consideration is that the median dura-
tion of follow-up of the cohort is still relatively short. All anti-
body testing was done in core reference laboratories with robust
quality assurance of long-term assay performance. The change
in GAD and IA-2/ICA512 antibody assays during the course of
the study does represent a potential weakness, but was
addressed by undertaking a large validation exercise which
demonstrated good concordance between the original and
new harmonised assays. Furthermore, the limited analysis
possible in subgroups of relatives identified as single antibody
positive using original and harmonised assays, showed similar
risk of developing additional antibodies (data not shown).
Because the harmonised GADA assay is generally more sensi-
tive than the BDC in-house 3H-leucine-labelled GAD65 assay
used in the early years of the study, the ‘appearance’ of GADA
for the first time in follow-up samples could potentially be an
artefact of the change of assay. We are, however, able to quan-
tify the possible impact of this and show that it would affect a
maximum of 12 of the 118 participants whom we have defined
as progressing to multiple autoantibody positivity (data not
shown). The optimal cutpoints for age and antibody titre that
we have used are empirical and would need to be validated in
an independent dataset if they were to be used for selection of
subgroups in future studies. Finally, as an international consor-
tium, TrialNet is not population-based and our study cohort was
heterogeneous but, although the findings may not be applicable
in all populations, we believe that the relatives recruited to the
study are likely to be representative of the potential participants
in future prevention studies.
Birth cohort studies have greatly clarified the natural history
of islet immunity in early life, demonstrating that, in popula-
tions at high genetic risk, autoantibodies generally appear in
infancy with rapid evolution of the broad immunoreactivity
typical of the disease-associated humoral immune response
characterised by antibodies to multiple islet autoantigens
[6–8]. The implications of antibodies to a single autoantigen
that appear in infancy but do not progress to the broader
response or are detected for the first time in childhood are
however less clear. Previous prospective studies have
shown that risk of progression to diabetes was substantially
lower in relatives who were positive for a single islet anti-
body than in those with two or more antibodies. The earliest
reports relied on initial screening for ICA by indirect
immunofluorescence and found that relatives with ICA
alone were at similar risk to those who were antibody negative
[2, 14]. Comparable results were subsequently seen for isolated
antibodies to GAD, IA-2/ICA512 or insulin in a number of
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Fig. 2 (a) Progression to type 1 diabetes in relatives positive for antibod-
ies to GAD (black line), insulin (dashed line) and IA-2/ICA512 (grey
line) (logrank test, p=0.662). (b) Progression to type 1 diabetes in rela-
tives who were confirmed multiple antibody positive at screening (grey
line) and those who progressed from confirmed single antibody positive
to confirmed multiple antibody positive from the time of progression
(black line) (logrank test, p<0.001)
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family study populations [15–17], when samples from relatives
screened for Diabetes Prevention Trial type 1 (DPT-1) were
re-tested for these [3] and in 1,533 single antibody positive
relatives included in an earlier TrialNet analysis [9]. It is,
however, clear that some individuals found to have single anti-
bodies at initial screening, and some previously antibody
negative relatives who develop antibodies for the first time
in later childhood or adult life [18], do progress to diabetes.
This analysis is, to our knowledge, the first to characterise
these in detail.
We have shown that progression from one stage of autoim-
munity to the next is not restricted to early childhood, but that
there appears to be a complementary, less aggressive pathway
for development of islet autoimmunity and risk of type 1
diabetes that continues beyond the first few years of life. In
contrast to the ‘classic’ pathway seen in infancy, in which the
first autoantibodies are generally directed against insulin, this
alternative route appears to start with autoimmunity directed
against GAD. Progression is associated with HLA-DR3-DQ2
and -DR4-DQ8 haplotypes, but while conversion to multiple
antibodies early in life has been found to be strongly
associated with DQ2/DQ8 and DQ8/DQ8 genotypes [6], the
risk in this older cohort is similar between high and moderate
risk HLA genotypes analysed. This concept of heterogeneity
in the autoimmune process is consistent with recent evidence
from The Environmental Determinants of Diabetes in the
Young study that, in infancy, the initiation of autoimmunity
to GAD and insulin differ in both timing and HLA
associations [19]. In addition, two distinct immunological
phenotypes—proinflammatory and partially regulated—
have been identified using multiparameter analysis of auto-
antibody and autoreactive T cell responses, complemented
by examination of the immunohistological characteristics
of insulitis in pancreas tissue collected from children and
adolescents who died soon after diagnosis of type 1 diabetes
[20].
Clearer definition of heterogeneity in the process leading to
type 1 diabetes and identifying the underlying mechanisms
have potentially important implications for disease prevention,
offering the possibility to target immunointervention strategies
more precisely [21]. It is estimated that some 50% of type 1
diabetes is diagnosed after age 20 years [22] and it is possible
that the slower course of adult onset type 1 diabetes results from
this alternative pathway.
A further implication is that this stepwise process offers the
opportunity to select intermediate endpoints for use in the
design of type 1 diabetes prevention trials [23] and therefore
to maximise the yield from screening relatives by offering a
variety of studies suitable for groups at different levels of risk.
We have demonstrated that transition from single to multiple
antibodies represents a progression in the disease process that
is associated with increased risk of clinical onset of diabetes.
Based on the results of this analysis, a placebo controlled study
that recruited around 280 relatives aged 8–20 years who are
positive for GADA alone would have 80% power to detect a
50% reduction in the observed rate of progression to multiple
antibodies over 5 years. Other autoantibody characteristics,
such as affinity and epitope specificity, may allow further strat-
ification of risk and facilitate the design and implementation of
prevention trials [24, 25]. The recently described
electrochemiluminescence assays for IAA and GADA and
substituting N-terminally truncated GAD65 (95–585) for full-
length GAD in the harmonised radiobinding assay have been
shown to improve disease specificity and more accurately
discriminate risk of progression to diabetes in single autoanti-
body positive individuals [26–28]. More detailed comparison
of the genetic characteristics—both HLA and non-MHC—
between the single autoantibody positive individuals who
develop additional autoantibodies and those who do not may
also refine risk assessment and provide insights into the
underlying autoimmune process.
In summary, we have demonstrated that a subset of rela-
tives positive for a single islet autoantibody is at risk of
progression of autoimmunity with the appearance of additional
autoantibodies in late childhood and adult life, and that this
change is associated with increased risk of diabetes. This
offers the opportunity to design innovative trials that comple-
ment those intervening in established advanced autoimmunity
or aiming to prevent its initiation.
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